REGN
REGN INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit
SAN DIEGO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of...
Read moreDetails
REGENERON THERAPEUTICS, INC. (NASDAQ: REGN) INVESTOR ALERT: Investors With Large Losses in Regeneron Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights
REGENERON THERAPEUTICS, INC. (NASDAQ: REGN) INVESTOR ALERT: Investors With Large Losses in Regeneron Therapeutics, Inc. Should Contact Bernstein Liebhard
Read moreDetails
Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025
TARRYTOWN, N.Y., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its...
Read moreDetails
1 Beaten-Down Stock That Could Soar by 50% in 2025, According to Wall Street
Biotech giant Regeneron Pharmaceuticals (REGN 1.08%) started 2024 on a strong note and performed well through the first half of...
Read moreDetails